NCT02605746 is a EARLY_PHASE1 clinical trial of ceritinib 750mg in Glioblastoma, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.

Who is sponsoring NCT02605746?

NCT02605746 is sponsored by St. Joseph's Hospital and Medical Center, Phoenix.

What drugs are being tested in NCT02605746?

Interventions in NCT02605746: ceritinib 750mg.

What condition does NCT02605746 study?

NCT02605746 studies Glioblastoma, Brain Metastases.

Is NCT02605746 still recruiting?

NCT02605746 is currently completed. Last updated 11 December 2020.

Last reviewed 2020-12-11 · How we verify

NCT02605746

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis

Completed EARLY_PHASE1 Last updated 11 December 2020

What this trial tests

EARLY_PHASE1 trial testing ceritinib 750mg in Glioblastoma in 10 participants. Completed in 12 July 2019.

Timeline

17 February 2016

Primary endpoint
29 November 2018

12 July 2019

Quick facts

Lead sponsor	St. Joseph's Hospital and Medical Center, Phoenix
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	10
Start date	17 February 2016
Primary completion	29 November 2018
Estimated completion	12 July 2019
Sites	1 location across United States

Drugs / interventions tested

ceritinib 750mg — full drug profile →

Conditions studied

Glioblastoma — all drugs for Glioblastoma →
Brain Metastases — all drugs for Brain Metastases →

Sponsor

St. Joseph's Hospital and Medical Center, Phoenix

Who can join

18 and older, any sex, with Glioblastoma or Brain Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is two parallel studies to examine pharmacokinetic (PK), pharmacodynamic (PD), and pharmacogenetic (PG) endpoints following short-interval therapy (10-14) daily doses without dose reduction and interruption) with the ALK (anaplastic lymphoma kinase) small-molecule inhibitor, ceritinib. The Phase 0 study will investigate: 1. first recurrence GBM patients and 2. patients with CNS metastases from solid tumors such as, but not limited to, NSCLC (non-small cell lung cancer) and melanoma. The CNS (central nervous system) metastases Phase 0 is designed to identify PK effects (in addition to PD, and PG effects on ALK-positive NSCLC metastases), while the GBM Phase 0 is designed to identify PK, PD, and PG effects in all patients.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma.
Mehta S, Fiorelli R, Bao X, Pennington-Krygier C, et al · · 2022 · cited 18× · PMID 34702773 · DOI 10.1158/1078-0432.ccr-21-1096
Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment.
Frumento D, Grossi G, Falesiedi M, Musumeci F, et al · · 2024 · cited 16× · PMID 38338677 · DOI 10.3390/ijms25031398
A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor.
Bao X, Wu J, Sanai N, Li J. · · 2018 · cited 13× · PMID 29568664 · DOI 10.1016/j.jpha.2017.07.007
Glioma Stem Cells-Features for New Therapy Design.
Pećina-Šlaus N, Hrašćan R. · · 2024 · cited 7× · PMID 38672638 · DOI 10.3390/cancers16081557
Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spaces-A Review.
Köllő Z, Garami M, Vincze I, Vásárhelyi B, et al · · 2023 · cited 1× · PMID 36678867 · DOI 10.3390/pharmaceutics15010239

Verify or expand the search:

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other St. Joseph's Hospital and Medical Center, Phoenix trials

Trials by the same sponsor.

NCT06177028 — MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment · Phase 2 · not yet recruiting
NCT06734286 — Working Memory Training in Patients with Mild Cognitive Impairment · NA · recruiting
NCT06578195 — ASSESS ALL ALS Study · recruiting
NCT06581861 — PREVENT ALL ALS Study · recruiting
NCT06019793 — Electrophysiological Recordings from Deep Brain Stimulation Electrodes for Pain · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02605746 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by St. Joseph's Hospital and Medical Center, Phoenix
Last refreshed: 11 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02605746.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing